Farallon Capital Management Adds $60M in Vaxcyte, Inc. ($PCVX)
Key Points
- Farallon Capital Management changed its Vaxcyte, Inc. ($PCVX) stake by 25120.0% last quarter, boosting to 1,261,000 shares worth $59.85 million.
- Wall Street's consensus rating on $PCVX is Strong Buy and an average price target of $109.00.
- $PCVX last traded around $47.46.
Farallon Capital Management increased its position in Vaxcyte, Inc. ($PCVX) by 25120.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,261,000 shares of Vaxcyte, Inc. after buying 1,256,000 shares during the quarter. Farallon Capital Management's holdings in Vaxcyte, Inc. were worth $59.85 million as of its most recent filing.
Vaxcyte, Inc. ($PCVX) Stock
Vaxcyte, Inc. Earnings
Analysts Set New Price Targets
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.